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Expanding applications of nanomaterials, particularly carbonaceous nanoparticles (CNP), in
new technologies, consumer products and biomedicine, imply their increasing levels of
manufacturing. In occupational and environmental settings, the lung is the major portal of
unintended CNP entry into the human body potentially leading to pulmonary damage,
inflammation, oxidative stress, fibrosis, and granuloma formation.[1,2] In addition, there are
numerous attempts to utilize nanoparticles for better delivery of drugs and nucleic acid-
based therapeutics to disease sites in the lung, particularly to the lung epithelium. The
inhalation of drug nano-formulations propelled the development of new strategies in therapy
of several human lung diseases such as asthma, cystic fibrosis, chronic obstructive
pulmonary disease, lung cancer, tuberculosis, etc.[3–6] Safety and lack of adverse health
effects remain the major prerequisites for broader applications of these novel technologies.
Toxicological assessments of nano-particles typically are performed on normal animals.[7]
Thus possible effects of CNP on tumor growth have not yet been considered. The immune
system safeguards the host from infections and malignancies. Recognition and undesirable
interactions of CNP with cells of the immune system may lead to immunomodulation, hence
increasing the host’s susceptibility to infections and cancer.[8] For instance, carbon
nanotubes (CNT) can generate oxidative stress and inflammation that can interfere with the
immune responses and, in turn, lead to enhanced susceptibility to and adverse outcomes
from pulmonary infection.[9] Whether CNT-induced immunosuppression can augment
tumor growth or alter tumor-host interactions is currently unknown. Here we report that
pulmonary CNT aspiration renders the host susceptible to lung carcinoma formation in the
murine metastasis/dissemination model. This effect was mediated by increased local and
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systemic accumulation of myeloid-derived suppressor cells (MDSC), as their depletion
abrogated tumor-supporting activity of CNT in vivo.
To determine whether Single Walled CNT (SWCNT) may affect tumor progression in vivo,
we utilized syngeneic metastatic Lewis lung carcinoma (LLC) as an approved model of
pulmonary metastatic disease in mice. Animals were pre-treated - via pharyngeal aspiration -
with short pristine (short-cut) CNT (average size: 230 nm; 80 μg/mouse) to avoid possible
pro-carcinogenic effects of CNT with high aspect ratios.[10] Of note, chemical cutting of
CNT is associated with the appearance of carboxy- and hydroxy-functionalities on their
surface.[11] Growth of transplanted tumor cells followed typical exponential kinetics with
the appearance of numerous tumor nodules in the lung by day 21 after i.v. tumor cell
inoculation. Morphologically, the lung tumors showed characteristic features of poorly-
differentiated non-small cell carcinoma, such as nuclear pleomorphism and hyperchromasia,
high nuclear/cytoplasmic ratio, brisk mitotic activity, extensive apoptosis and small areas of
necrosis (Figure 1). Exposure of mice to SWCNT prior to tumor cell injection resulted in
significant acceleration of tumor growth revealed by several parameters. First, the weight of
the lungs in tumor-bearing animals, reflecting the overall tumor burden, increased up to 5-
fold in SWCNT-treated mice compared to the control group of mice (without CNT
exposure) (Figure 1c). Second, SWCNT pre-treatment caused significant, up to 2.5-fold,
elevation of the number of visible pulmonary macro-metastasis (Figure 1a,c), as well as
increasing the total area of metastatic nodules upon histopathology evaluation of the lung
tissues (Figure 1b). In control tumor-bearing mice, the tumor nodules were of different size,
but collectively comprised about 25% of tissue on the slides. Pre-treatment with SWCNT
caused the appearance of significantly larger tumor nodules than in control group, resulting
in up to a 3-fold increase in their collective area on tissue slides (Figure 1d). SWCNT did
not change the typical morphological features of tumor, but accelerated tumor growth and
the appearance of intratumoral necrosis zones, associated with rapid tumor growth (Figure
1). These data indicate that exposure of SWCNT promoted establishment and growth of
pulmonary metastasis in mice in vivo.
Next, we explored whether the tumor-supporting activity of CNT may be associated with the
modulation of the tumor immunoenvironment. Myeloid-derived suppressor cells are one of
the main cell populations responsible for regulating the host immune responses to
tumors.[12] MDSC, among other myeloid regulatory cells, are accumulated in tumor-bearing
hosts and support tumor growth and progression by inhibiting antitumor immunity,
stimulating intratumoral neoangiogenesis, and sustaining tumor cell spreading and
metastases.[13] Thus, we examined whether SWCNT exposure affected MDSC in the lungs.
We found that SWCNT significantly up-regulated the generation and systemic homing of
granulocytic MDSC. Elevated numbers of CD11b+Ly6G+Ly6Clow MDSC were detected in
the lung, spleen and bone marrow of SWCNT-treated tumor-free animals 48 h after CNT
administration (Figure 2a,b).
Based on the detected CNT induced marked acute accumulation of MDSC in lymphoid and
non-lymphoid tissues, we hypothesized that the presence of MDSC in the lungs might
support the local in growth of tumor cells. To test this, we first characterized MDSC in
tumor-bearing mice. As anticipated, three weeks after tumor inoculation, control tumor-
bearing mice showed a significant increase, up to 3–4-fold, in the amount of granulocytic
MDSC in the lung, spleen and bone marrow as compared to non-tumor-bearing animals
(Figure 2c). However, the levels of MDSC accumulation in lungs, but not in the lymphoid
tissues, were additionally significantly increased up to 2-fold in SWCNT-pre-treated animals
as compared to vehicle-treated controls (Figure 2c). This robust enhancement of MDSC
accumulation by CNT pre-exposure was evident when either the total numbers of MDSC
subsets were quantified or when their amounts were normalized by the total population of
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CD45+ leucocytes in the tissues with different levels of tumor burden (Figure 2c). The
elevated levels of MDSC may be due to the overall increase of tumor burden in CNT-treated
mice and/or initial up-regulation of MDSC accumulation after CNT inhalation, as shown
above. However, significantly higher levels of MDSC in the lungs of CNT-pretreated mice
support the latter mechanism. Alternatively, expansion of regulatory T cells (Tregs) in the
tumor environment has been suggested to confer tumor growth and metastatic advantages by
inhibiting antitumor immunity.[14] However, neither SWCNT exposure nor administration
of LLC cells up-regulated accumulation of CD4+CD25+FoxP3+ regulatory T cells in mice,
as shown, for example for splenic Treg cells (Figure S2). This is in line with the data in the
literature where no alterations of Treg cells have been revealed for a number of different
tumor models.[15, 16]
Growth of LLC cell-derived tumors may be associated with the accumulation of
immunosuppressive regulatory dendritic cells (regDC) [17, 18] and exposure to CNT may
alter DC in vivo resulting in systemic immune suppression.[19] Therefore, we next assessed
different subsets of DC in control and treated mice. Based on the co-expression of CD11b
and CD11c molecules[20] we confirmed that progression of lung metastases was
accompanied by decreased levels of conventional CD11chighCD11blow/neg DC and increased
accumulation of immature CD11chighCD11bhigh DC and regulatory CD11clowCD11bhigh
DC in the lung cancer microenvironment (Figure 2d,e). Exposure of mice to SWCNT prior
to tumor cell administration did not cause significant alterations in DC subsets, suggesting
that down-regulation of conventional DC and up-regulation of immature DC and regDC
cannot explain the strong tumor growth stimulation effect of CNT administration.
Assuming that acceleration of tumor formation and growth in the lung induced by CNT pre-
exposure is due to up-regulation of MDSC, we reasoned that depletion of MDSC may lead
to suppression of metastatic growth of tumors. We used anti-Gr-1 Ab[21] to deplete MDSC.
We found that anti-Gr-1 Ab effectively prevented CNT-induced up-regulation of MDSC in
the lungs and spleen (Figure 3a). Therefore, we tested whether anti-Gr-1 Ab pretreatment of
animals would affect CNT-enhanced metastatic growth of lung tumors by suppressing the
MDSC expansion. Remarkably, selective elimination of MDSC induced by the pre-
treatment with anti-Gr-1 Ab, completely blocked CNT-mediated acceleration of the
formation and growth of lung metastases (Figure 3b). Specifically, neither the number of
macro-metastases (193.8% versus 108.1% increase in mice without and with MDSC
depletion, respectively; p<0.05) nor the weight of the lungs (432.2% versus 93.8% increase
in mice without and with MDSC depletion, respectively; p<0.05) were altered as a result of
exposure to CNT. These results were confirmed by pathohistological examination of the
lung tissues (Figure 3c) demonstrating the similar levels of micrometastasis formation in
control and CNT-pretreated tumor-bearing mice after initial depletion of MDSC induced by
pre-exposure to CNT. Sections in both groups show small nodules of poorly-differentiated
non-small cell carcinoma with the largest measuring 1–2 mm in greatest dimension. At high
power, tumor cells show nuclear pleomorphism and hyperchromasia, high nuclear/
cytoplasmic ratio, brisk mitotic activity, extensive apoptosis and mild intratumoral and
peritumoral leukocytic infiltration. These data provide strong evidence in favor of up-
regulation of MDSC accumulation as an important mechanism contributing to CNT induced
enhanced metastatic growth of lung carcinoma.
Several reports have alerted to the potential carcinogenicity of high aspect ratio CNT.[10, 22]
In-vitro studies indirectly suggest the potential carcinogenicity of CNT based on their ability
to induce DNA damage, and the activation of signal transduction pathways related to
asbestos-induced lung cancer and mesothelioma.[23, 24] It has been also reported that
prolonged exposure of human lung epithelial cell line to SWCNT in cultures induced
malignant transformation of treated cells, which obtained the ability to form subcutaneous
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tumors in a xenograft model with immunodeficient mice.[25] However, the possibility of
CNT’s action on host-tumor interactions and growth of tumors has not been considered. In
this study, we employed non-pristine (chemically-cut) CNT containing carboxy- and
hydroxy-functionalities on their surface. Our data indicate that non-pristine CNT promote
metastatic tumor establishment and growth by altering the tissue microenvironment,
specifically by facilitating MDSC accumulation. Notably, it has been shown that effects of
CNT on cells, including (geno)toxicity in vitro and in vivo, may differ significantly for
pristine and functionalized nanotubes being strongly dependent on the type of functional
groups on their surface.[26] Overall, carboxylated and hydroxylated CNT may exert stronger
modifying effects than pristine nanotubes.[27–29] It is likely that inflammatory MDSC
induced by pulmonary exposure to CNT support the initial tumor cell homing in the lung
and then are polarized into tumor-associated MDSC. The latter are known to block the
development of anti-tumor immunity hence facilitate tumor growth by producing specific
growth factors and cytokines that also stimulate intratumoral neoangiogenesis. However,
possible effects of nanoparticles on systemic immune reaction invoked by tumor progression
have not been addressed so far. Further studies of the specific pathways through which CNT
and other nanoparticles may affect the immune cells in the tumor microenvironment and
cause immunosuppression and unresponsiveness are warranted. This will lead to the design
of tumor-specific theranostics platforms with modules capable of depleting or functionally
suppressing MDSC (and other myeloid regulatory cells) to ensure effective
immunosurveillance in the tumor microenvironment.
EXPERIMENTAL SECTION
Experimental procedures are provided in the Supporting Information section of the paper.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Acute exposure to SWCNT accelerated formation and growth of lung carcinoma
Pathogen-free female C57BL6/J mice received SWCNT (80 μg/mouse) by pharyngeal
aspiration 48 h prior to Lewis lung carcinoma cells (LLC, 3×105 cells) via the tail vein and
sacrificed 3 weeks later. The lungs were collected for visualization and counting of
macroscopic tumor nodules (a,c), weight (c) and immunohistochemical (IHC) analysis of
micrometastases after H&E staining (b,d). Lungs with tumor nodules (circled) and IHC of
lung specimens with micrometastases (arrows) (x100) (b) are shown from a representative
experiments. The average weight of the lungs and number of tumor nodules were calculated
from 4 independent experiments with 7–8 mice/group in each experiment (c). The average
collective areas of lung carcinoma on tissue slides are shown for LLC and SWCNT+LLC
groups (d). *, p<0.05 (Student t-test, n=4).
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Figure 2. Single aspiration of SWCNT up-regulated accumulation of MDSC in tumor-free and
tumor-bearing mice but did not up-regulate immature and regulatory dendritic cell subsets in
tumor-bearing mice
The levels of monocytic CD11b+Ly6GnegLy6Chigh (area 1) and granulocytic
CD11b+Ly6G+Ly6Clow/neg (area 2) MDSC in the lymphoid tissues and lungs in tumor-free
C57Bl6/J mice 48 h after SWCNT (80 μg/mouse) or PBS (control group) pharyngeal
aspiration were assessed by flow cytometry (a) and statistical analysis of data from 4
independent experiments each with 7–8 mice/group is shown as the mean ± SEM of
accumulated polymorphonuclear MDSC *, p<0.05 (Student t-test, n=4) (b). Accumulation
of MDSC in the lungs and lymphoid tissues in tumor-free and LCC-bearing mice pre-treated
with SWCNT (80 μg/mouse) were assessed 21 days after administration of LLC cells
(3×105 cells) or PBS (control groups). The results are shown as the percentage of MDSC
among total cells (black bars) and CD45+ leukocytes (green bars). *, p<0.05 versus Control
group; #, p<0.05 versus LLC group (One-way ANOVA, n=4) (c). Similarly, the levels of
conventional (CD11chighCD11blow/neg) (area 1), immature (CD11chighCD11bhigh) (area 2)
and regulatory (CD11clowCD11bhigh) (area 3) DC subsets in tumor-free and tumor-bearing
mice were assessed in the lungs and spleens three weeks after LLC cell (3×105 cells)
inoculation by flow cytometry (d) and distribution of these DC subsets are represented from
experiment of 7–8 mice/group. The results are shown as the percentage of DC among total
cells. *, p<0.05 versus Control group (One-way ANOVA, n=3) (e).
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Figure 3. Depletion of SWCNT-induced MDSC suppressed metastatic growth of lung tumors
Depletion of MDSC was carried out using Ly-6G/Ly-6C (Gr-1) antibody. (a) Analysis of
CD11b+Gr-1+ MDSC in tumor-free C57BL6/J mice 48 h after SWCNT (80 μg/mouse)
pharyngeal aspiration. Control animals received PBS aspiration and rat IgG Ab (i.p., 50 μg/
day). The results are the mean of MDSC percentage among total cells ± SEM from two
independent experiments with 6–7 mice per group in each experiment. *, p<0.05 versus
Control group (One-way ANOVA); #, p<0.05 versus SWCNT group (One-way ANOVA).
(b) Formation of visual macro-metastases in mice 3 weeks after LLC cell (3×105)
administration and pre-treatment with SWCNT (80 μg/mouse). Although depletion of
MDSC decreased formation of lung metastases, it completely blocked the stimulating effect
of SWCNT aspiration on tumor formation. The results are the mean ± SEM from 3
independent experiments with 6–7 mice/group in each experiment. *, p<0.05 versus other
groups (One-way ANOVA). (c) Histopathological analysis of micrometastases in the lungs
of C57BL6/J mice treated with SWCNT (low panels) or PBS (control, upper panels)
following by MDSC depletion and sacrificed 3 weeks after LLC cell (3×105) inoculation
(x100 and x400). H&E stained slides demonstrated the presence of similar small nodules of
poorly-differentiated non-small cell carcinoma in both groups with the similar levels of
micrometastasis formation.
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